Earnings call transcript: SIGA Technologies Q4 2025 shows mixed market reaction

SIGA reported full-year 2025 revenue of $95M and net income of $23M (FY diluted EPS $0.32) with a cash balance of $155M and no debt, while Q4 produced an EPS loss of -$0.08. The stock fell 2.23% in after-hours trading then rebounded 4.53% premarket; the company has $26M of outstanding U.S. government orders, secured a $13M international multi-year order and received $27M in government funding for development. Regulatory uncertainty exists over the mpox indication in Europe and the business remains highly dependent on U.S. government procurements, implying timing-driven quarterly volatility.

Analysis

The company sits at the intersection of two binary event paths: government procurement cycles and regulatory labeling in Europe. A favorable government procurement decision materially re-rates the business because it converts discretionary international interest into predictable, lumpy contracts; conversely, a regulatory setback narrows commercial use cases and amplifies headline-driven selling even if underlying stockpile demand remains intact.

Because production is domestically concentrated and historically tied to government stockpiles, any material new award will stress fill-rate dynamics and create multi-quarter recognition patterns rather than a smooth revenue ramp—this is a capacity and timing story as much as a demand one. That implies dealers and algos will continue to trade the name on flow/timing news, producing outsized option-volatility opportunities around procurement announcements and regulatory milestones.

The international wins coming from repeat customers are a leading indicator of secular reappraisal of national biodefense budgets in Asia-Pacific and Europe; rising geopolitical risk makes multi-year stockpiling more politically palatable, increasing optionality on follow-on orders. Second-order beneficiaries include domestic CDMOs, sterile-fill and cold-chain logistics providers that will be first called when order sizes jump, creating attractive event-driven pair trades.

Key tail risks are a sustained government reprioritization (budget or policy) or an adverse EU regulatory conclusion that triggers de-listing in certain markets; both would compress forward visibility and re-rate multiples quickly. Near-term catalysts to monitor are formal procurement RFPs and the next regulatory committee pronouncement—both create 30–90 day windows of heightened directional exposure.

Key Decisions for Investors

• Long SIGA (SIGA): buy a 9–12 month call spread to capture upside from potential procurement awards and follow-on international orders; structure to cap premium (max loss = premium) while targeting 2–3x payoff if a material contract is announced within 12 months. Hedge: buy a cheap 2–3 month put if holding equity into the next regulatory milestone to protect against immediate derating.
• Event-hedge SIGA (SIGA): for holders who want downside protection without selling, buy 3-month puts sized to cover position delta ahead of the upcoming regulatory committee window; cost is limited and insures against headline-driven 20–40% drawdowns that historically follow adverse biotech regulatory news.
• Tactical long on risk-on flows via UBS (UBS): buy a 3–6 month call (or outright shares if comfortable) to play potential asset-manager and brokerage flow into equities if macro sentiment shifts toward preparedness-driven defense spending. Keep position size small as a portfolio flyer—reward is exposure to a broader re-risking trade while risk is capped to premium or share capital.